Relationship between platelet-derived growth factors and clinical and clinical-dynamic characteristics in patients with mood disorders

Relationship between platelet-derived growth factors and clinical and clinical-dynamic characteristics in patients with mood disorders

 

Authors

 

U.V. Ryazantseva

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation

A.S. Boiko

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation

L.A. Levchuk

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation

G.G. Simutkin

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation

S.A. Ivanova

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation; Federal State Budgetary Educational Institution of Higher Education “Siberian State Medical University” of the Ministry of Health of the Russian Federation, Tomsk, Russian Federation

S.N. Vasilieva

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation

O.V. Roshchina

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation

N.A. Bokhan

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation; Federal State Budgetary Educational Institution of Higher Education “Siberian State Medical University” of the Ministry of Health of the Russian Federation, Tomsk, Russian Federation; Federal State Autonomous Educational Institution of Higher Education “National Research Tomsk State University”, Tomsk, Russian Federation

 

https://doi.org/10.26617/1810-3111-2024-2(123)-5-12

 

Journal: Siberian Herald of Psychiatry and Addiction Psychiatry. 2024; 2 (123):  5-12

 

Abstract

Background. Significant heterogeneity in the clinical manifestations of mood disorders (MDs) complicates the diagnosis and selection of therapy in some cases. Currently, the search for biological markers of clinical manifestations is a promising area of research. One of the potential markers are platelet-derived growth factors – PDGF-AA and PDGF-BB. Objective: to determine the relationship between the level of platelet growth factors PDGF-AA and PDGF-BB with clinical and clinical-dynamic characteristics in patients with mood disorders. Materials and Methods. A study of 85 patients with mood disorders (bipolar disorder, depressive episode, recurrent depressive disorder) was carried out based on the Laboratory of Molecular Genetics and Biochemistry and the Affective States Department of the clinics of Mental Health Research Institute of Tomsk National Research Medical Center. For the clinical and psychopathological assessment of the patients' condition over time, the following psychometric tools were used: the Hamilton Depression Rating Scale (HDRS-17), the Hamilton Anxiety Rating Scale (HARS), the Clinical Global Impression of Illness Severity (CGI-S) scale, and the Snaith-Hamilton Pleasure Scale (SHAPS), Social Adaptation Self-evaluation Scale (SASS). The concentration of growth factors in the blood serum of patients was determined by the multiplex method using multiplex flow analyzers Magpix and Luminex 200 (Luminex, USA). Results. When measuring the levels of platelet-derived growth factors in patients with MDs, statistically significantly higher levels of both PDGF-AA and PDGF-BB were found compared with the corresponding indicators in mentally and physically healthy controls. It was found that the level of PDGF-AA positively correlated with the duration of MDs and the level of anhedonia on the SHAPS. Negative correlations were found between the level of PDGF-AA and indicators of the severity of anxiety, indicators of the severity of the disorder on the CGI-S scale, and the level of social adaptation on the SASS. When determining the correlation between the studied clinical and clinical-dynamic characteristics and the concentration of the platelet factor PDGF-BB, correlations were found: positive ‒ between PDGF-BB indicators, duration of MDs and the level of anhedonia, negative ‒ between PDGF-BB indicators and severity of the disease on the CGI-S scale, as well as indicators of subjective assessment of the level of social adaptation on the SASS. Conclusion. The study revealed relationships between the levels of platelet growth factors, clinical and clinical-dynamic characteristics of patients with mood disorders.

 

Keywords: mood disorders, depression, biomarkers of mood disorders, neuroinflammation, platelet-derived growth factors.

 

Article (pdf)

 

Contacts

 

This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Materials  

For citation: Ryazantseva U.V., Boiko A.S., Levchuk L.A., Simutkin G.G., Ivanova S.A., Vasilieva S.N., Roshchina O.V., Bokhan N.A. Relationship between platelet-derived growth factors and clinical and clinical-dynamic characteristics in patients with mood disorders.Siberian Herald of Psychiatry and Addiction Psychiatry.2024; 2 (123): 5-12. https://doi.org/10.26617/1810-3111-2024-2(123)-5-12

 

REFERENCES

  1. Institute of Health Metrics and Evaluation. Global Health Data Exchange (GHDx). https://vizhub.healthdata.org/gbd-results/ (Accessed 4 March 2023).
  2. Krasnov VN. Problems of modern diagnosis of depression. S.S. Korsakov Journal of Neurology and Psychiatry. Special issues. 2012;112(11 2):3 10 (in Russian).
  3. Petrunko OV. Predicting the development of chronic depressive disorder. Siberian Herald of Psychiatry and Addiction Psychiatry. 2022;3(116):30-36. https://doi.org/10.26617/1810-3111-2022-3(116)-30-36 (in Russian).
  4. Smulevich AB. Depression and comorbid disorders. Moscow, 1997:308(in Russian).
  5. Levchuk LA, Bokhan NA, Ivanova SA. Neurospecific proteins as transdiagnostic markers of affective disorders. NeurochemicalJournal. 2023;40(1):30-34 doi: 10.31857/S1027813323010119 (inRussian).
  6. Roshchina OV, Levchuk LA, Simutkin GG, Ivanova SA, Bokhan NA. Relationship between neurospecific serum proteins and clinical manifestations in a depressive episode and recurrent depressive disorder. Psychiatry (Moscow). 2023;21(4):42-48.
  7. Mednova IA, Levchuk LA, Boiko AS, Roschina OV, Simutkin GG, Bokhan NA, Loonen AJM, Ivanova SA. Cytokine level in patients with mood disorder, alcohol use disorder and their comorbidity. World J Biol Psychiatry. 2023 Mar;24(3):243-253. doi: 10.1080/15622975.2022.2095439. Epub 2022 Jul 25. PMID: 35818961.
  8. Grigoriyan GA, Dygalo NN, Gekht AB, Stepanichev MYu, Gulyaeva NV. Molecular cellular mechanisms of depression. Role of glucocorticoids, cytokines, neurotransmitters and trophic factors in the genesis of depressive disorders. Advances in Physiological Sciences. 2014;45(2):3-19 (in Russian).
  9. Vasilieva EF, Brusov OS. Cellular and molecular mechanisms of the participation of pro-inflammatory monocytes in the pathogenesis of mental disorders. Part 2. Psychiatry (Moscow). 2020;18(4):81-92. doi:10.30629/2618-6667-2020-18-4-81-92 (in Russian).
  10. Boiko AS, Mednova IA, Kornetova EG, Bokhan NA, Ivanova SA. Serum growth factors in schizophrenia patients. Curr Issues Mol Biol. 2023 Apr 7;45(4):3291-3301. doi: 10.3390/cimb45040215. PMID: 37185739; PMCID: PMC10136551.
  11. MikhalitskayaEV, LevchukLA. Brain neuroplasticity: brain-derived neurotrophic factor and protein kinase signaling pathways (literature review).Siberian Herald of Psychiatry and Addiction Psychiatry.2022;3(116):44-53. https://doi.org/10.26617/1810-3111-2022-3(116)-44-53(in Russian).
  12. Idemoto K, Ishima T, Niitsu T, Hata T, Yoshida S, Hattori K, Horai T, Otsuka I, Yamamori H, Toda S, Kameno Y, Ota K, Oda Y, Kimura A, Hashimoto T, Mori N, Kikuchi M, Minabe Y, Hashimoto R, Hishimoto A, Nakagome K, Iyo M, Hashimoto K. Platelet-derived growth factor BB: A potential diagnostic blood biomarker for differentiating bipolar disorder from major depressive disorder. J Psychiatr Res. 2021 Feb; 134:48-56. doi: 10.1016/j.jpsychires.2020.12.051. Epub 2020 Dec 21. PMID: 33360224.
  13. Nguyen PT, Nakamura T, Hori E, Urakawa S, Uwano T, Zhao J, Li R, Bac ND, Hamashima T, Ishii Y, Matsushima T, Ono T, Sasahara M, Nishijo H. Cognitive and socio-emotional deficits in platelet-derived growth factor receptor-β gene knockout mice. PLoS One. 2011 Mar 18;6(3):e18004. doi: 10.1371/journal.pone.0018004. PMID: 21437241; PMCID: PMC3060876.
  14. Funa K, Sasahara M. The roles of PDGF in development and during neurogenesis in the normal and diseased nervous system. J Neuroimmune Pharmacol. 2014 Mar;9(2):168-81. doi: 10.1007/s11481-013-9479-z. Epub 2013 Jun 15. PMID: 23771592; PMCID: PMC3955130.
  15. Kapoor A, Nation DA; Alzheimer’s Disease Neuroimaging Initiative. Platelet-derived growth factor-BB and white matter hyperintensity burden in APOE4 carriers. Cereb Circ Cogn Behav. 2022;3:100131. doi: 10.1016/j.cccb.2022.100131. Epub 2022 Mar 1. PMID: 35844252; PMCID: PMC9286493.
  16. Luttenbacher I, Phillips A, Kazemi R, Hadipour AL, Sanghvi I, Martinez J, Adamson MM. Transdiagnostic role of glutamate and white matter damage in neuropsychiatric disorders: A systematic review. J Psychiatr Res. 2022 Mar;147:324-348. doi: 10.1016/j.jpsychires.2021.12.042. Epub 2021 Dec 28. PMID: 35151030.
  17. Zou K, Huang X, Li T, Gong Q, Li Z, Ou-yang L, Deng W, Chen Q, Li C, Ding Y, Sun X. Alterations of white matter integrity in adults with major depressive disorder: a magnetic resonance imaging study. J Psychiatry Neurosci. 2008 Nov;33(6):525-30. PMID: 18982175; PMCID: PMC2575756.
  18. Poletti S, Paolini M, Ernst J, Bollettini I, Melloni E, Vai B, Harrington Y, Bravi B, Calesella F, Lorenzi C, Zanardi R, Benedetti F. Long-term effect of childhood trauma: Role of inflammation and white matter in mood disorders. Brain Behav Immun Health. 2022 Oct 3;26:100529. doi: 10.1016/j.bbih.2022.100529. PMID: 36237478; PMCID: PMC9550612.
  19. Lei S, Lu WY, Xiong ZG, Orser BA, Valenzuela CF, MacDonald JF. Platelet-derived growth factor receptor-induced feed-forward inhibition of excitatory transmission between hippocampal pyramidal neurons. J Biol Chem. 1999 Oct 22;274(43):30617-23. doi: 10.1074/jbc.274.43.30617. PMID: 10521446.
  20. Li HH, Liu Y, Chen HS, Wang J, Li YK, Zhao Y, Sun R, He JG, Wang F, Chen JG. PDGF-BB-Dependent Neurogenesis Buffers Depressive-Like Behaviors by Inhibition of GABAergic Projection from Medial Septum to Dentate Gyrus. Adv Sci (Weinh). 2023 Aug;10(22):e2301110. doi: 10.1002/advs.202301110. Epub 2023 Jun 16. PMID: 37325895; PMCID: PMC10401107.